News
BioProcess Insider: Grist for the MIL: CDMO Cognate making cell therapies for WindMIL

WindMIL Therapeutics has upped a contract with Cognate BioServices to make its marrow-infiltrating lymphocyte (MIL) cell therapies

WindMIL Therapeutics and Cognate BioServices Announce Agreement to Expand MILs Manufacturing Capacity

WindMIL Therapeutics and Cognate BioServices, Inc. today announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.

WindMIL Therapeutics Appoints Patrick Fabbio as Chief Financial Officer

WindMIL Therapeutics today announced the appointment of Patrick Fabbio as Chief Financial Officer, effective March 30. Mr. Fabbio brings more than 25 years of financial, operational and transactional leadership experience in both publicly traded and privately held life science and pharmaceutical companies to this role. He will lead development and execution of the company’s financial […]

BioCentury Emerging Company Profile – WindMIL: T cell source is key

(article behind paywall)

WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics and Providence Cancer Institute today announced that the first patient has been identified in an investigator-sponsored study for the collection of bone marrow from patients with breast cancer. The study will evaluate generating marrow-infiltrating lymphocytes (MILs™) for patients through WindMIL’s proprietary cellular activation and expansion process. The study is being conducted at the […]

WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania

WindMIL Therapeutics today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings. The collaboration will leverage WindMIL’s and Penn’s respective expertise to conduct pre-clinical comparisons of the characteristics and functionality of CAR-T and CAR-MIL products.

WindMIL Therapeutics Announces Expansion of Leadership Team

WindMIL Therapeutics today announced the expansion of its leadership team with the appointment of Karen LaRochelle as Senior Vice President, Corporate & Business Development and the promotion of Patrick Dougherty to Senior Vice President, Strategy, Planning & Operations.

WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to evaluate the safety and efficacy of WindMIL Therapeutics’ marrow-infiltrating lymphocytes (MILs™) in combination with Bristol-Myers Squibb’s nivolumab (Opdivo®), a PD-1 immune checkpoint inhibitor, in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who […]

WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced that the first patient has been dosed in a Phase 2a clinical trial to determine the safety and efficacy of MILs alone and in combination with an anti-PD-1 in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to or have relapsed on an anti-PD-1-containing […]

WindMIL Therapeutics to Present Data Demonstrating Superior Efficacy of CAR-T cells using Marrow-Infiltrating Lymphocytes (CAR-MILs™) Compared to Peripheral Blood Lymphocytes at the 61st American Society of Hematology Annual Meeting and Exposition

WindMIL Therapeutics will present new data in a poster presentation on Monday, December 9, 2019, at the 61st American Society of Hematology Annual Meeting and Exposition (ASH), demonstrating that chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) possess superior anti-tumor immunity compared to traditional CAR-T cells engineered using peripheral blood lymphocytes (CAR-PBLs).